Principal Financial Group Inc. Sells 9,329 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Principal Financial Group Inc. lowered its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 3.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 247,427 shares of the company’s stock after selling 9,329 shares during the period. Principal Financial Group Inc.’s holdings in Pacira BioSciences were worth $3,724,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. ProShare Advisors LLC grew its holdings in Pacira BioSciences by 8.0% during the first quarter. ProShare Advisors LLC now owns 12,461 shares of the company’s stock worth $364,000 after purchasing an additional 924 shares during the period. GAMMA Investing LLC lifted its position in Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after acquiring an additional 932 shares during the last quarter. Outfitter Financial LLC lifted its position in Pacira BioSciences by 5.7% during the second quarter. Outfitter Financial LLC now owns 20,190 shares of the company’s stock worth $578,000 after acquiring an additional 1,095 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Pacira BioSciences by 6.0% during the second quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company’s stock worth $685,000 after acquiring an additional 1,354 shares during the last quarter. Finally, Park Place Capital Corp acquired a new stake in Pacira BioSciences during the second quarter worth approximately $46,000. Institutional investors own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Barclays cut their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Piper Sandler downgraded shares of Pacira BioSciences from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Pacira BioSciences in a research report on Friday, November 8th. Finally, Raymond James downgraded shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $23.50.

Pacira BioSciences Stock Up 2.1 %

Shares of PCRX opened at $17.38 on Friday. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95. The company has a market cap of $802.43 million, a P/E ratio of -8.56 and a beta of 0.82. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The firm has a 50 day simple moving average of $16.02 and a two-hundred day simple moving average of $20.42.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.